Financial Performance - As of March 31, 2025, the company's total revenue reached $14.31 million, representing a year-over-year increase of 13.92% [1] - The net profit attributable to the parent company was -$0.8612 million, showing a significant decrease of 307.79% compared to the previous year [1] Company Overview - The company, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on the biopharmaceutical, bio-extraction, and healthcare sectors [1] - The product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium [1] Product Applications - Tetracycline raw materials are used not only for producing human antibiotics but also support the global aquaculture and livestock industries, ensuring the safety of poultry and seafood [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, which are major anticoagulants [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]
博美集团上涨4.49%，报8.84美元/股，总市值16.26亿美元